Search News Year All202620252024202320222021 08/05/2026 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update Read More 08/04/2026 Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference Read More 08/03/2026 Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) Read More 07/24/2026 Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union Read More 07/22/2026 Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call Read More 06/23/2026 Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) Read More 06/11/2026 Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition Read More 06/08/2026 Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA Read More 05/29/2026 Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More 05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More
08/03/2026 Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) Read More
07/24/2026 Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union Read More
06/23/2026 Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) Read More
06/11/2026 Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition Read More
06/08/2026 Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA Read More
05/29/2026 Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More
05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More
News
Careers
Contacts